Search

Your search keyword '"Uemura, Hiroji"' showing total 987 results
Start Over Author "Uemura, Hiroji" Publication Year Range Last 10 years
987 results on '"Uemura, Hiroji"'

2. Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy

Author

Rosenberg, Jonathan E., Mamtani, Ronac, Sonpavde, Guru P., Loriot, Yohann, Duran, Ignacio, Lee, Jae-Lyun, Matsubara, Nobuaki, Vulsteke, Christof, Castellano, Daniel, Sridhar, Srikala S., Pappot, Helle, Gurney, Howard, Bedke, Jens, van der Heijden, Michiel S., Galli, Luca, Keam, Bhumsuk, Masumori, Naoya, Meran, Johannes, O'Donnell, Peter H., Park, Se Hoon, Grande, Enrique, Sengeløv, Lisa, Uemura, Hiroji, Skaltsa, Konstantina, Campbell, Mary, Matsangou, Maria, Wu, Chunzhang, Hepp, Zsolt, McKay, Caroline, Powles, Thomas, and Petrylak, Daniel P.

Published
2024
Full Text
View/download PDF

10. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

Author

Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher J., Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ross, Efstathiou, Eleni, Efstathiou, Jason, Ekeke, Onyeanunam Ngozi, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Dan, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara A., Jones, Rob, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raja, Logothetis, Christopher, Mahal, Brandon, Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O’Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel J., Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark A., Ryan, Charles J., Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, and Omlin, Aurelius

Published
2023
Full Text
View/download PDF

11. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher, Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Ngozi Ekeke, Onyeanunam, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Daniel, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara Alicja, Jones, Robert, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raya, Logothetis, Christopher J., Mahal, Brandon A., Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark. A., Ryan, Charles J., Saad, Fred, Pablo Sade, Juan, Sartor, Oliver A., Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, and Omlin, Aurelius

Published
2023
Full Text
View/download PDF

13. MP05-07 GDF15 PROPEPTIDE IS A NOVEL BLOOD BIOMARKER FOR CASTRATION-RESISTANT PROSTATE CANCER WITH BONE METASTASIS VIA PROMOTING THE VICIOUS CYCLE

Author

Yamamichi, Gaku, primary, Kato, Taigo, additional, Arakawa, Noriaki, additional, Motoyama, Yuichi, additional, Outani, Hidetatsu, additional, Myoba, Shohei, additional, Ishizuya, Yu, additional, Yamamoto, Yoshiyuki, additional, Hatano, Koji, additional, Kawashima, Atsunari, additional, Uemura, Hiroji, additional, Uemura, Motohide, additional, and Nonomura, Norio, additional

Published
2024
Full Text
View/download PDF

15. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Gillessen, Silke, Armstrong, Andrew, Attard, Gert, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Bossi, Alberto, Briganti, Alberto, Bristow, Robert G., Bulbul, Muhammad, Caffo, Orazio, Chi, Kim N., Clarke, Caroline S., Clarke, Noel, Davis, Ian D., de Bono, Johann S., Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Ekeke, Onyeanunam Ngozi, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fizazi, Karim, Frydenberg, Mark, George, Dan, Gleave, Martin, Halabi, Susan, Heinrich, Daniel, Higano, Celesta, Hofman, Michael S., Hussain, Maha, James, Nick, Jones, Robert, Kanesvaran, Ravindran, Khauli, Raja B., Klotz, Laurence, Leibowitz, Raya, Logothetis, Chris, Maluf, Fernando, Millman, Robin, Morgans, Alicia K., Morris, Michael J., Mottet, Nicolas, Mrabti, Hind, Murphy, Declan G., Murthy, Vedang, Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Parker, Chris, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Rob E., Rubin, Mark, Ryan, Charles J., Saad, Fred, Sade, Juan P., Sartor, Oliver, Scher, Howard I., Shore, Neal, Skoneczna, Iwona, Small, Eric, Smith, Matthew, Soule, Howard, Spratt, Daniel E., Sternberg, Cora N., Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Tombal, Bertrand, Türkeri, Levent, Uemura, Hiroji, Uemura, Hirotsugu, van Oort, Inge, Yamoah, Kosj, Ye, Dingwei, Zapatero, Almudena, and Omlin, Aurelius

Published
2022
Full Text
View/download PDF

18. Current issues and management consensus of advanced prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference—JAPAN 2023.

Author

Hashimoto, Kohei, Kosaka, Takeo, Terada, Naoki, Kimura, Takahiro, Nonomura, Norio, Suzuki, Hiroyoshi, and Uemura, Hiroji

Subjects
UROLOGISTS, PHYSICIANS, PROSTATE cancer, VOTING, MEDICAL care
Abstract

Objective: To evaluate and compare the voting results of Japanese urologists with the global panel at the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Methods: Among the 198 questions discussed at the APCCC 2022, the APCCC‐JAPAN 2023 focused on 14 key questions related to the management of advanced prostate cancer with insufficient high‐level evidence based on their relevance to the Japanese cohort. A panel of six prostate cancer experts addressed these 14 questions and presented the latest evidence to Japanese urologists who voted on‐site using a web‐based system. The results were compared with those of APCCC 2022. Results: This study found significant differences in the voting results between Japanese urologists and the global panel regarding several crucial issues related to advanced prostate cancer management. These differences were those observed in treatment preferences, monitoring strategies, and treatment choices in specific clinical scenarios. These findings highlight the need for a nuanced approach tailored to the unique challenges with considerations of the Japanese healthcare environment. Conclusions: APCCC‐JAPAN 2023 provides valuable insights into the current clinical issues surrounding the management of advanced prostate cancer in Japan. The partial divergence in the consensus between Japanese urologists and the global panel underscores the importance of a context‐specific approach. The results of this study provide practical guidance for physicians facing complex challenges and should be used to inform decision‐making in the management of advanced prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Prostate ductal adenocarcinoma exhibiting a late recurrence in the anterior urethra 13 years post-total prostatectomy: a case report.

Author

Honda, Seiichiro, Kawahara, Takashi, Tanaka, Reiko, Yuguchi, Shu, Yamanaka, Shoji, Fujii, Satoshi, Hasizume, Akihito, Osaka, Kimito, Mimura, Noboru, Karibe, Jurii, Noguchi, Takeaki, Shimokihara, Kota, Takamoto, Daiji, Takeshima, Teppei, Teranishi, Jun-ichi, Makiyama, Kazuhide, and Uemura, Hiroji

Subjects
URETHRAL cancer, PROSTATE-specific antigen, LYMPHATIC metastasis, RADICAL prostatectomy, GLEASON grading system, PROSTATE cancer
Abstract

Background: Prostate ductal adenocarcinoma, a rare histology observed in 0.4–0.8% of all prostate cancers, is treated similarly to acinar adenocarcinoma but tends to have a higher likelihood of metastasis, recurrence, and poorer prognosis. Case presentation: A 73-year-old Asian-Japanese male presented with gross hematuria, with investigations revealing a prostate ductal adenocarcinoma. Subsequent radical prostatectomy indicated a Gleason score of 8 with no lymph node metastasis. Despite initial prostate-specific antigen level reductions post-prostatectomy and salvage radiation therapy due to recurring elevated prostate-specific antigen levels, no recurrence was evident until 13 years later. A tumor in the anterior urethra was identified as metastasis of his prostate ductal adenocarcinoma. Conclusion: This report presents an uncommon case of prostate ductal adenocarcinoma exhibiting a late recurrence in the anterior urethra 13 years post-radical prostatectomy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Laparoscopic removal of retroperitoneal schwannoma in renal hilum: a case report.

Author

Yamamoto, Shotaro, Kawahara, Takashi, Saito, Tomoki, Hanai, Takahiro, Takeshima, Teppei, Maeda, Koki, Makiyama, Kazuhide, and Uemura, Hiroji

Subjects
KIDNEY tumors, RENAL veins, KIDNEY physiology, PORTAL vein, TUMORS
Abstract

Background: Schwannomas in the renal hilum are rare among retroperitoneal tumors. However, the possibility of malignant findings cannot be ruled out, and surgery is often indicated. This case was expected to be difficult to remove laparoscopically because the tumor was sandwiched between the arteriovenous veins of the renal portal. Sometimes, the tumor should be resected with a conservative approach to the kidney to preserve the renal function. Case presentation: Our patient was a 51-year-old Asian-Japanese man who was referred to our department for a retroperitoneal tumor in the renal hilum. Since malignancy could not be ruled out due to its size (45 × 48 × 55 mm) on imaging, the tumor was excised laparoscopically. Histopathology revealed schwannoma. Conclusions: We herein report a case in which a renal hilar tumor between renal arteriovenous vessels was successfully resected laparoscopically. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Supplementary Methods S1 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Author

Dorff, Tanya, primary, Horvath, Lisa G., primary, Autio, Karen, primary, Bernard-Tessier, Alice, primary, Rettig, Matthew B., primary, Machiels, Jean-Pascal, primary, Bilen, Mehmet A., primary, Lolkema, Martijn P., primary, Adra, Nabil, primary, Rottey, Sylvie, primary, Greil, Richard, primary, Matsubara, Nobuaki, primary, Tan, Daniel S.W., primary, Wong, Alvin, primary, Uemura, Hiroji, primary, Lemech, Charlotte, primary, Meran, Johannes, primary, Yu, Youfei, primary, Minocha, Mukul, primary, McComb, Mason, primary, Penny, Hweixian Leong, primary, Gupta, Vinita, primary, Hu, Xuguang, primary, Jurida, Gabor, primary, Kouros-Mehr, Hosein, primary, Janát-Amsbury, Margit M., primary, Eggert, Tobias, primary, and Tran, Ben, primary

Published
2024
Full Text
View/download PDF

24. Supplementary Table S3 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Author

Dorff, Tanya, primary, Horvath, Lisa G., primary, Autio, Karen, primary, Bernard-Tessier, Alice, primary, Rettig, Matthew B., primary, Machiels, Jean-Pascal, primary, Bilen, Mehmet A., primary, Lolkema, Martijn P., primary, Adra, Nabil, primary, Rottey, Sylvie, primary, Greil, Richard, primary, Matsubara, Nobuaki, primary, Tan, Daniel S.W., primary, Wong, Alvin, primary, Uemura, Hiroji, primary, Lemech, Charlotte, primary, Meran, Johannes, primary, Yu, Youfei, primary, Minocha, Mukul, primary, McComb, Mason, primary, Penny, Hweixian Leong, primary, Gupta, Vinita, primary, Hu, Xuguang, primary, Jurida, Gabor, primary, Kouros-Mehr, Hosein, primary, Janát-Amsbury, Margit M., primary, Eggert, Tobias, primary, and Tran, Ben, primary

Published
2024
Full Text
View/download PDF

25. Supplementary Figure S2 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Author

Dorff, Tanya, primary, Horvath, Lisa G., primary, Autio, Karen, primary, Bernard-Tessier, Alice, primary, Rettig, Matthew B., primary, Machiels, Jean-Pascal, primary, Bilen, Mehmet A., primary, Lolkema, Martijn P., primary, Adra, Nabil, primary, Rottey, Sylvie, primary, Greil, Richard, primary, Matsubara, Nobuaki, primary, Tan, Daniel S.W., primary, Wong, Alvin, primary, Uemura, Hiroji, primary, Lemech, Charlotte, primary, Meran, Johannes, primary, Yu, Youfei, primary, Minocha, Mukul, primary, McComb, Mason, primary, Penny, Hweixian Leong, primary, Gupta, Vinita, primary, Hu, Xuguang, primary, Jurida, Gabor, primary, Kouros-Mehr, Hosein, primary, Janát-Amsbury, Margit M., primary, Eggert, Tobias, primary, and Tran, Ben, primary

Published
2024
Full Text
View/download PDF

26. Data from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Author

Dorff, Tanya, primary, Horvath, Lisa G., primary, Autio, Karen, primary, Bernard-Tessier, Alice, primary, Rettig, Matthew B., primary, Machiels, Jean-Pascal, primary, Bilen, Mehmet A., primary, Lolkema, Martijn P., primary, Adra, Nabil, primary, Rottey, Sylvie, primary, Greil, Richard, primary, Matsubara, Nobuaki, primary, Tan, Daniel S.W., primary, Wong, Alvin, primary, Uemura, Hiroji, primary, Lemech, Charlotte, primary, Meran, Johannes, primary, Yu, Youfei, primary, Minocha, Mukul, primary, McComb, Mason, primary, Penny, Hweixian Leong, primary, Gupta, Vinita, primary, Hu, Xuguang, primary, Jurida, Gabor, primary, Kouros-Mehr, Hosein, primary, Janát-Amsbury, Margit M., primary, Eggert, Tobias, primary, and Tran, Ben, primary

Published
2024
Full Text
View/download PDF

27. Supplementary Tables S1-S5 from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

Author

Nishiyama, Hiroyuki, primary, Yonese, Junji, primary, Kawahara, Takashi, primary, Matsumoto, Ryuji, primary, Miyake, Hideaki, primary, Matsubara, Nobuaki, primary, Uemura, Hiroji, primary, Eto, Masatoshi, primary, Azuma, Haruhito, primary, Obara, Wataru, primary, Terai, Akito, primary, Fukasawa, Satoshi, primary, and Suekane, Shigetaka, primary

Published
2024
Full Text
View/download PDF

28. Data from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

Author

Nishiyama, Hiroyuki, primary, Yonese, Junji, primary, Kawahara, Takashi, primary, Matsumoto, Ryuji, primary, Miyake, Hideaki, primary, Matsubara, Nobuaki, primary, Uemura, Hiroji, primary, Eto, Masatoshi, primary, Azuma, Haruhito, primary, Obara, Wataru, primary, Terai, Akito, primary, Fukasawa, Satoshi, primary, and Suekane, Shigetaka, primary

Published
2024
Full Text
View/download PDF

29. Supplementary Legends from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

Author

Nishiyama, Hiroyuki, primary, Yonese, Junji, primary, Kawahara, Takashi, primary, Matsumoto, Ryuji, primary, Miyake, Hideaki, primary, Matsubara, Nobuaki, primary, Uemura, Hiroji, primary, Eto, Masatoshi, primary, Azuma, Haruhito, primary, Obara, Wataru, primary, Terai, Akito, primary, Fukasawa, Satoshi, primary, and Suekane, Shigetaka, primary

Published
2024
Full Text
View/download PDF

30. Supplementary Figure S1 from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

Author

Nishiyama, Hiroyuki, primary, Yonese, Junji, primary, Kawahara, Takashi, primary, Matsumoto, Ryuji, primary, Miyake, Hideaki, primary, Matsubara, Nobuaki, primary, Uemura, Hiroji, primary, Eto, Masatoshi, primary, Azuma, Haruhito, primary, Obara, Wataru, primary, Terai, Akito, primary, Fukasawa, Satoshi, primary, and Suekane, Shigetaka, primary

Published
2024
Full Text
View/download PDF

31. SETD2 regulates SLC family transporter-mediated sodium and glucose reabsorptions in renal tubule

Author

Mitome, Taku, primary, Wakui, Hiromichi, additional, Azushima, Kengo, additional, Uehara, Tatsuki, additional, Jikuya, Ryosuke, additional, Ohtake, Shinji, additional, Noguchi, Go, additional, Kawaura, Sachi, additional, Iribe, Yasuhiro, additional, Aomori, Kota, additional, Tatenuma, Tomoyuki, additional, Ito, Hiroki, additional, Kawahara, Takashi, additional, Komeya, Mitsuru, additional, Ito, Yusuke, additional, Muraoka, Kentaro, additional, Furuya, Mitsuko, additional, Kato, Ikuma, additional, Fujii, Satoshi, additional, Nagahama, Kiyotaka, additional, Nishiyama, Akira, additional, Tamura, Tomohiko, additional, Kimura, Yayoi, additional, Kawagoe, Tatsukata, additional, Mizuki, Nobuhisa, additional, Huang, Gang, additional, Uemura, Hiroji, additional, Yao, Masahiro, additional, Makiyama, Kazuhide, additional, Tamura, Kouichi, additional, and Hasumi, Hisashi, additional

Published
2024
Full Text
View/download PDF

32. Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network

Author

Merseburger, Axel S., primary, Bakshi, Ganesh, additional, Chen, Dong-Yi, additional, Chiong, Edmund, additional, Jabbour, Michel, additional, Joung, Jae Young, additional, Lai, Allen Yu-Hung, additional, Lawrentschuk, Nathan, additional, Le, Tuan-Anh, additional, Ng, Chi Fai, additional, Ng, Choon Ta, additional, Ong, Teng Aik, additional, Pang, Jacob See-Tong, additional, Rabah, Danny M., additional, Ragavan, Narasimhan, additional, Sase, Kazuhiro, additional, Suzuki, Hiroyoshi, additional, Teo, Michelle Mui Hian, additional, Uemura, Hiroji, additional, and Woo, Henry H., additional

Published
2024
Full Text
View/download PDF

35. A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer

Author

Dorff, Tanya, primary, Horvath, Lisa G., additional, Autio, Karen, additional, Bernard-Tessier, Alice, additional, Rettig, Matthew B., additional, Machiels, Jean-Pascal, additional, Bilen, Mehmet A., additional, Lolkema, Martijn P., additional, Adra, Nabil, additional, Rottey, Sylvie, additional, Greil, Richard, additional, Matsubara, Nobuaki, additional, Tan, Daniel S.W., additional, Wong, Alvin, additional, Uemura, Hiroji, additional, Lemech, Charlotte, additional, Meran, Johannes, additional, Yu, Youfei, additional, Minocha, Mukul, additional, McComb, Mason, additional, Penny, Hweixian Leong., additional, Gupta, Vinita, additional, Hu, Xuguang, additional, Jurida, Gabor, additional, Kouros-Mehr, Hosein, additional, Janát-Amsbury, Margit M., additional, Eggert, Tobias, additional, and Tran, Ben, additional

Published
2024
Full Text
View/download PDF

38. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Author

Park, Se Hoon, van der Heijden, Michiel S., Necchi, Andrea, Castellano, Daniel, Bamias, Aristotelis, Lee, Jae Lyun, De Giorgi, Ugo, Bögemann, Martin, Eigl, Bernhard J., Tsiatas, Marinos, Powles, Thomas, Novikov, Andrey, Skoneczna, Iwona, Mukherjee, Som D., Suarez, Cristina, Westgeest, Hans, Fradet, Yves, Flechon, Aude, Ou, Yen-Chuan, Park, Inkeun, Matveev, Vsevolod, Pérez-Valderrama, Begoña, Cheng, Susanna, Frank, Stephen, Gurney, Howard, Anido, Urbano, Hamzaj, Alketa, Retz, Margitta, Sridhar, Srikala, Scagliotti, Giorgio Vittorio, Voortman, Jens, Alekseev, Boris, Alyasova, Anna, Komyakov, Boris, Dumez, Herlinde, Pavic, Michel, Kimura, Go, Mizokami, Atsushi, Osanto, Susanne, Arranz, Jose Angel, Piersma, Djura, Shin, Sang Joon, Karyakin, Oleg, Delgado, Ignacio, Gonzalez, Jose Luis, Pang, See-Tong, Tran, Anna, Lipatov, Oleg, Su, Wen-Pin, Flaig, Thomas, Alva, Ajjai, Park Kyong, Hwa, Kopyltsov, Evgeny, Almagro, Elena, Domenech, Monserrat, Chang, Yen-Hwa, Sautois, Brieuc, Ravaux, Andre, Aravantinos, Gerasimos, Georgoulias, Vasileios, Mulder, Sasja, Kim, Yu Jung, Kater, Fabio, Chevreau, Christine, Tagawa, Scott, Zalewski, Pawel, Joly, Florence, Loriot, Yohann, Hatiboglu, Gencay, Gianni, Luca, Morelli, Franco, Tambaro, Rosa, Hashimoto, Yasuhiro, Nosov, Alexander, Font, Albert, Rodriguez-Vida, Alejo M., Jones, Robert, Vasudev, Naveen, Srinivas, Sandhya, Zhang, Jingsong, Gil, Thierry, Finch, Daygen, Grimm, Marc-Oliver, Su, Yu-Li, Chowdhury, Simon, Hocking, Christopher, Plas, Eugen, North, Scott, Jensen, Niels Viggo, Theodore, Christine, Imkamp, Florian, Peer, Avivit, Kobayashi, Takashi, Sakai, Hideki, Sassa, Naoto, Yoshimura, Kazuhiro, Aarts, Maureen, Ferreira Castro, Ana, Topuzov, Marlen, Rodriguez, Juan Francisco, Vazquez, Federico Jose, Tsai, Yu-Chieh, Crabb, Simon, Hussain, Syed, Bendell, Johanna, Gross-Goupil, Marine, Gwenaelle, Gravis, Berger, Raanan, Statsenko, Galina, Evans, Linda, Drakaki, Alexandra, Somer, Bradley, Davis, Ian, Lynam, James, Borges, Giuliano, Dettino, Aldo, Fay, André P., Martins, Graziella, Zucca, Luis Eduardo, Agerbaek, Mads, Kalofonos, Haralambos, Rosenbaum, Eli, Enokida, Hideki, Kikukawa, Hiroaki, Nishimura, Kazuo, Tamada, Satoshi, Uemura, Motohide, Lopez, Yamil, Gietema, Jourik, Slojewski, Marcin, Fernandes, Isabel, Smolin, Alexey, Mazhar, Danish, Kalebasty, Arash Rezazadeh, Carthon, Bradley, Loidl, Wolfgang, Franke, Fabio, Girotto, Gustavo, Alimohamed, Nimira, Macfarlane, Robyn, Pappot, Helle, Niegisch, Guenter, Mavroudis, Dimitrios, Sella, Avishay, Porta, Camillo, Ebara, Shin, Nakamura, Motonobu, Obara, Wataru, Okuno, Norihiko, Shinohara, Nobuo, Sugimoto, Mikio, Suzuki, Akitaka, Tokuda, Noriaki, Uemura, Hiroji, Yamaguchi, Akito, Ramirez, Francisco, Rozanowski, Pawel, Wiechno, Pawel, Keam, Bhumsuk, Kislov, Nikolay, Plaksin, Denis, Cicin, Irfan, Kumar, Satish, Galsky, Matthew D., Petrylak, Daniel P., Rosales, Joseph, Vaishampayan, Ulka, Culine, Stephane, Papandreou, Christos, Nara, Taketoshi, Erman, Mustafa, Kreiger, Laurence, Janoski, Juliana, Rosa, Diogo, Siqueira, Mariana, Canil, Christina, Sengelov, Lisa, Tourani, Jean-Marc, Arai, Gaku, Hashine, Katsuyoshi, Kawakita, Mutsushi, Nakaigawa, Noboru, Nomi, Hayahito, Shiina, Hiroaki, Suzuki, Hiroyoshi, Yonese, Junji, Kuri, Roberto, Macedo, Eleazar, Rivera, Samuel, Villalobos Prieto, Alberto, Polakiewicz-Gilowska, Anna, Zaucha, Renata, Lopes, Fabio, Ponomarev, Roman, Pomerantz, Mark, Shariat, Shahrokh, Luk, Cynthia, Lesniewski-Kmak, Krzysztof, van der Heijden, Michiel S, Galsky, Matthew D, Petrylak, Daniel P, Ogawa, Osamu, Lee, Jae-Lyun, Eigl, Bernhard J, Mukherjee, Som D, Suárez, Cristina, Fay, André P, Duran, Ignacio, Wildsmith, Sophie, He, Philip, Angra, Natasha, Gupta, Ashok K, Levin, Wendy, and Bellmunt, Joaquim

Published
2020
Full Text
View/download PDF

39. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial

Author

Uemura, Hiroji, Matsushima, Hisashi, Kobayashi, Kazuki, Mizusawa, Hiroya, Nishimatsu, Hiroaki, Fizazi, Karim, Smith, Matthew, Shore, Neal, Tammela, Teuvo, Tabata, Ken-ichi, Matsubara, Nobuaki, Iinuma, Masahiro, Uemura, Hirotsugu, Oya, Mototsugu, Momma, Tetsuo, Kawakita, Mutsushi, Fukasawa, Satoshi, Kobayashi, Tadahiro, Kuss, Iris, Le Berre, Marie-Aude, Snapir, Amir, Sarapohja, Toni, and Suzuki, Kazuhiro

Published
2021
Full Text
View/download PDF

40. Japanese clinical practice guidelines for prostate cancer 2023.

Author

Kohjimoto, Yasuo, Uemura, Hiroji, Yoshida, Masahiro, Hinotsu, Shiro, Takahashi, Satoru, Takeuchi, Tsutomu, Suzuki, Kazuhiro, Shinmoto, Hiroshi, Tamada, Tsutomu, Inoue, Takahiro, Sugimoto, Mikio, Takenaka, Atsushi, Habuchi, Tomonori, Ishikawa, Hitoshi, Mizowaki, Takashi, Saito, Shiro, Miyake, Hideaki, Matsubara, Nobuaki, Nonomura, Norio, and Sakai, Hideki

Subjects
*PROSTATE cancer, *MEDICAL quality control, *PROSTATE cancer patients
Abstract

This fourth edition of the Japanese Clinical Practice Guidelines for Prostate Cancer 2023 is compiled. It was revised under the leadership of the Japanese Urological Association, with members selected from multiple academic societies and related organizations (Japan Radiological Society, Japanese Society for Radiation Oncology, the Department of EBM and guidelines, Japan Council for Quality Health Care (Minds), Japanese Society of Pathology, and the patient group (NPO Prostate Cancer Patients Association)), in accordance with the Minds Manual for Guideline Development (2020 ver. 3.0). The most important feature of this revision is the adoption of systematic reviews (SRs) in determining recommendations for 14 clinical questions (CQs). Qualitative SRs for these questions were conducted, and the final recommendations were made based on the results through the votes of 24 members of the guideline development group. Five algorithms based on these results were also created. Contents not covered by the SRs, which are considered textbook material, have been described in the general statement. In the general statement, a literature search for 14 areas was conducted; then, based on the general statement and CQs of the Japanese Clinical Practice Guidelines for Prostate Cancer 2016, the findings revealed after the 2016 guidelines were mainly described. This article provides an overview of these guidelines. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Enzalutamide Prolonged the Duration of Drug Use in Comparison to Abiraterone Acetate and Cabazitaxel after Upfront Docetaxel: A Large Japanese Database Study.

Author

Yamaguchi, Katsuya, Kawahara, Takashi, Hashizume, Akihito, Ousaka, Kimito, Uemura, Koichi, Ito, Yusuke, Ito, Hiroki, Makiyama, Kazuhide, and Uemura, Hiroji

Subjects
CASTRATION-resistant prostate cancer, DOCETAXEL, BONE metastasis, MEDICAL coding, CANCER patients, ABIRATERONE acetate
Abstract

Introduction: In the United States, a total of 268,490 men were found to have prostate cancer in 2022, thus making it the most common cancer in men, accounting for 27% of all cancers in the male population. Among all cancers in men, it was the fifth leading cause of death, with 34,500 deaths and a mortality rate of 11%. In 2019, the total number of cases was 94,748, making it the leading cancer in males, accounting for 11% of all male cancers. In terms of mortality, it ranked seventh, with 13,217 deaths and a mortality rate of 1.6%. However, new treatment options for metastatic castration-sensitive prostate cancer (mCSPC) have emerged. Docetaxel has been shown to be effective for both mCSPC and castration-resistant prostate cancer (CRPC). Upfront docetaxel has not been approved in Japan, nor has it been validated in large-scale studies. Furthermore, several agents can be used after docetaxel treatment, but it is unclear which is the most effective. We used a large Japanese health insurance database to determine which agent would be the most effective as a next-line therapy in patients who had received docetaxel. Materials and Methods: We used data from medical institutions using the Diagnosis Procedure Combination (DPC), which provides a comprehensive evaluation of medical classifications. The Medical Data Vision database covers approximately 23% of DPC hospitals in Japan. This study analyzed 2938 patients with mCSPC who received docetaxel, followed by CRPC, between April 2008 and December 2021. The study focused on three agents: enzalutamide, abiraterone acetate, and cabazitaxel. Other agents were excluded due to the small number of patients. The following data were analyzed: age, date of CRPC diagnosis, presence of bone metastasis, drug type, and prognosis. Results: This study included 1997 patients with CRPC after upfront docetaxel therapy for mCSPC (enzalutamide [ENZ] group, n = 998; abiraterone acetate [ABI] group, n = 617; and cabazitaxel [CBZ] group, n = 382). The overall survival (OS) time from drug initiation was 456 days in the enzalutamide group, which was significantly longer than that in the cabazitaxel group (p = 0.017, HR 0.94) (ENZ: ABI p = 0.54, HR 0.94; ABI: CBZ p = 0.14, HR 0.75). OS was also compared for the third-line drug in the group that received enzalutamide as the second-line drug, the group that used abiraterone acetate as the third-line drug (ENZ-ABI group), and the group that used abiraterone acetate as the second-line drug. OS from the start of the third-line drug was compared between the ENZ–ABI group and the ABI–ENZ group, which received enzalutamide as the third-line drug, but showed no significant difference (269 vs. 281 days, p = 0.85; HR 1.03). Conclusion: ENZ was shown to prolong OS relative to cabazitaxel after the cessation of docetaxel. ENZ was associated with a longer duration of drug use than ABI and CBZ. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real‐world data.

Author

Uemura, Koichi, Ito, Hiroki, Jikuya, Ryosuke, Kondo, Takuya, Tatenuma, Tomoyuki, Kawahara, Takashi, Ito, Yusuke, Komeya, Mitsuru, Muraoka, Kentaro, Hasumi, Hisashi, Uemura, Hiroji, and Makiyama, Kazuhide

Subjects
TRANSITIONAL cell carcinoma, OVERALL survival, PEMBROLIZUMAB, ANTIBODY-drug conjugates, ELECTRIC vehicles
Abstract

Objective: In December 2021, enfortumab vedotin (EV), an antibody‐drug conjugate directed against nectin‐4, was approved in Japan as a new treatment after platinum‐containing chemotherapy and PD‐1/PD‐L1 inhibitors. This study evaluated, using real‐world data, the efficacy and safety of EV therapy in patients with metastatic urothelial carcinoma (mUC). Materials and methods: Fifty‐five patients with mUC who discontinued pembrolizumab therapy due to disease progression between June 2018 and April 2023 at Yokohama City University Hospital were evaluated retrospectively. Of the 55 patients, 25 received EV therapy (EV group) and 30 did not (non‐EV group). All patients who underwent EV therapy were diagnosed with disease progression after the approval of EV in Japan. Results: The median (range) follow‐up period after pembrolizumab discontinuation was 6.3 (0.7–31.1) months. There were eight (32.0%) deaths due to cancer in the EV group and 27 (90.0%) in the non‐EV group. The overall survival (OS) after pembrolizumab discontinuation was not reached in the EV group versus 2.6 months in the non‐EV group (p < 0.001). A multivariate analysis revealed that EV therapy (EV vs. non‐EV group; hazard ratio 0.26; 95% confidence interval 0.16–0.41; p < 0.001) was an independent prognostic factor for OS. Conclusion: EV prolonged OS in mUC following pembrolizumab therapy in real‐world data. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

Author

Nishiyama, Hiroyuki, primary, Yonese, Junji, additional, Kawahara, Takashi, additional, Matsumoto, Ryuji, additional, Miyake, Hideaki, additional, Matsubara, Nobuaki, additional, Uemura, Hiroji, additional, Eto, Masatoshi, additional, Azuma, Haruhito, additional, Obara, Wataru, additional, Terai, Akito, additional, Fukasawa, Satoshi, additional, and Suekane, Shigetaka, additional

Published
2023
Full Text
View/download PDF

45. Angiotensin II receptor blockers reduce the need to perform a prostate biopsy

Author

Uemura, Hiroji, primary, Kawahara, Takashi, additional, Itoh, Yusuke, additional, Kobayashi, Kazuki, additional, Takizawa, Akitoshi, additional, Ohta, Jun-ichi, additional, Udagawa, Kouichi, additional, Maeda-Minami, Ayako, additional, Mano, Yasunari, additional, Mutoh, Michihiro, additional, Matsuyama, Yutaka, additional, and Ishikawa, Hideki, additional

Published
2023
Full Text
View/download PDF

46. Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis

Author

Hayashi, Narihiko, Osaka, Kimito, Muraoka, Kentaro, Hasumi, Hisashi, Makiyama, Kazuhide, Kondo, Keiichi, Nakaigawa, Noboru, Yao, Masahiro, Mukai, Yuki, Sugiura, Madoka, Takano, Shoko, Ito, Eiko, Kaizu, Hisashi, Koike, Izumi, Hata, Masaharu, Taguri, Masataka, Miyoshi, Yasuhide, Izumi, Koji, Kawahara, Takashi, and Uemura, Hiroji

Published
2020
Full Text
View/download PDF

47. A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study

Author

Matsubara, Nobuaki, Kimura, Go, Uemura, Hiroji, Uemura, Hirotsugu, Nakamura, Motonobu, Nagamori, Satoshi, Mizokami, Atsushi, Kikukawa, Hiroaki, Hosono, Makoto, Kinuya, Seigo, Krissel, Heiko, Siegel, Jonathan, and Kakehi, Yoshiyuki

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results